SAN DIEGO - February 24, 2009 - Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced positive results from the second of two double-blind pivotal Phase 3 trials assessing the safety and ...

SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...

Researchers have identified new roles for a protein long known to protect against severe flu infection -- among them, raising the minimum number of viral particles needed to cause sickness.

Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease ...

In a recent article published in the bioRxiv* preprint server, researchers examined immune reflexes towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women.

Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Note: Hover over the donut graph to view ...

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or ...

Article ‘Count’ and ‘Share’ for Structural Molecular Biology and Infectious Process based on listed parameters only. The articles listed below published by authors from Structural Molecular Biology ...